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Abstract 
The mitochondrion has fundamental roles in the production of energy as ATP, the regulation 
of cell viability and apoptosis, and the biosynthesis of major structural and regulatory molecules, 
such as lipids. During ATP production reactive oxygen species are generated that alter the 
intracellular redox state and activate apoptosis. Mitochondrial dysfunction is a well recognized 
component of the pathogenesis of diseases such as cancer. Understanding mitochondrial function, 
and how this is dysregulated in disease, offers the opportunity for the development of drug 
molecules to specifically target such defects. Altered energy metabolism in cancer, in which ATP 
production occurs largely by glycolysis, rather than by oxidative phosphorylation, is attributable in 
part to the upregulation of cell survival signaling cascades. These pathways also regulate the 
balance between pro- and anti-apoptotic factors that may determine the rate of cell death and 
proliferation. A number of anticancer drugs have been developed that target these factors and one of 
the most promising groups of agents in this regard are the lipid-based molecules that act directly or 
indirectly at the mitochondrion. These molecules have emerged in part from an understanding of the 
mitochondrial actions of naturally occurring fatty acids. Some of these agents have already entered 
clinical trials because they specifically target known mitochondrial defects in the cancer cell. 
Keywords  N-acylethanolamines, cancer cell, ether phospholipids, fatty acid 
biotransformation, free fatty acids, intrinsic pathway of apoptosis, mitochondrial 
ATP production, polyunsaturated fatty acid epoxides, reactive oxygen species 
Abbreviations Caspase, cysteine-aspartic protease; CLA, conjugated linoleic acid; COX, 
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HETE, hydroxyeicosatetraenoic acid; JNK, Jun-N-terminal kinase; LOX, 
lipoxygenase; MAP kinase, mitogen-activated protein kinase; PI3K, 
phosphatidylinositol 3’ kinase; PG, prostaglandin; PUFA, polyunsaturated fatty 
acid; ROS, reactive oxygen species; TTA, tetradecylthioacetic acid 
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Mitochondrial function: Introduction 
The mitochondrion has a number of critical homeostatic functions, including the production 
of energy as ATP, the control of apoptotic cell death and viability, and the biosynthesis of 
molecules such as steroids and lipids that perform regulatory and structural roles in cells (Kroemer 
et al., 2007). Mitochondria are also the major source of reactive oxygen species (ROS) that 
determine the intracellular redox state and modulate cell proliferation and apoptosis. It is 
increasingly recognized that disease processes, such as tumourigenesis and the metabolic syndrome, 
are associated with mitochondrial dysfunction (Kroemer et al., 2007). A detailed understanding of 
how the regulation of mitochondrial function is altered during cancer progression may provide 
opportunities for drug design strategies that target underlying defects in disease. 
 
Mitochondrial energy production and altered ATP generation in cancer cells 
The role of the mitochondrion in energy metabolism is well established and glucose is the 
primary fuel molecule utilized by the cell in ATP production (Kroemer et al., 2007). The initial 
glycolytic step occurs in the cytoplasm of the cell and generates pyruvate that enters the 
mitochondrion where it is converted to citrate; together these two reactions produce four molecules 
of ATP from each molecule of glucose. In addition, four large multi-protein respiratory complexes 
in the inner mitochondrial membrane work in concert to generate a much larger number of ATPs by 
oxidative phosphorylation (~28-32 per glucose molecule). Simultaneously this builds up the proton 
gradient across the inner and outer mitochondrial membranes that drives many mitochondrial 
processes. 
Fats and proteins may also be utilized by the mitochondrion to produce ATP (Kroemer et 
al., 2007). Triglyceride esters in adipose tissue are hydrolysed to free fatty acids that undergo 
mitochondrial β-oxidation to acetyl-CoA units that are then able to enter the citric acid cycle and 
generate ATP. The oxidative deamination of amino acids produces up to 15% of total metabolic 
energy in animals. In the initial phase, amino acids are converted to a series of intermediary 
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molecules - pyruvate, α-ketoglutarate, succinyl-CoA, fumarate, oxaloacetate, acetyl-CoA and 
acetoacetate – that may then enter the citric acid cycle and generate ATP. 
Whereas normal cells generate much of their ATP by oxidative phosphorylation, aggressive 
cancer cells exhibit pronounced bioenergetic differences and overproduce lactate even under 
normoxic conditions by “aerobic glycolysis” (Rossignol et al., 2004). This occurs because most of 
the pyruvate formed by glycolysis is unable to enter the mitochondrion, and is instead converted to 
lactate by cytosolic lactate dehydrogenase.  
 
Mitochondria and ROS production: activation of the intrinsic pathway of apoptosis  
The ROS H2O2, superoxide (O2−), and hydroxyl radical (OH−) are generated by 
mitochondrial respiratory complexes during uncoupled substrate turnover in the process of ATP 
formation (Cadenas and Davies, 2000; Hanahan and Weinberg, 2011). Premature leakage of 
electrons from respiratory complexes, rather than coupled transfer during ATP synthesis, leads to 
superoxide formation (Skulachev, 1998; Di Paola and Lorusso, 2006; Pike et al., 2011). The 
mitochondrion is not only the main site of ROS generation it is also their primary target. The 
generation of ROS has several consequences in cells, including direct peroxidative damage to 
membranes and modification of DNA bases that may initiate mutagenesis (Larsen et al., 2005; 
Nathan and Cunningham-Bussel, 2013). ROS also modulate cellular redox homeostasis (Higdon et 
al., 2012) and decrease the concentration of thiol-containing species, such as glutathione, that are 
cytoprotective (Mari et al., 2009). Indeed, glutathione depletion decreases the integrity and 
activities of mitochondrial respiratory complexes, which compromises ATP production and cell 
viability (Merad-Boudia et al., 1998). More recently it has been recognized that ROS are also able 
to activate the Jun-N-terminal kinase (JNK; Trachootham et al., 2006) and p38 mitogen-activated 
protein (MAP) kinase (Ito et al., 2006) signaling pathways that may trigger apoptotic cell death.  
Apoptosis is a coordinated cell-death program that is important in normal tissues (Fulda and 
Debatin, 2006). There are two major pathways of apoptosis: the extrinsic and intrinsic pathways. In 
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the extrinsic pathway tumour necrosis factor family receptors at the plasma membrane are activated 
by FasL and related ligands and modulate intracellular signaling pathways leading to cell deletion. 
The intrinsic, or mitochondrial, pathway of apoptosis is activated intracellularly by ROS, the 
inhibition of pro-survival signaling cascades, or by major cellular stresses, including DNA damage 
from exposure to cytotoxic anticancer drugs. 
The relative ratio of pro- and anti-apoptotic Bcl-2 family proteins is a determinant of the 
response of cells to apoptotic stimuli (Fulda and Debatin, 2006). Thus, pro-apoptotic Bcl-2 proteins, 
such as Bax, Bak and Bid, form dimers that destabilize the outer mitochondrial membrane to 
apoptotic stimuli by forming channels that allow mitochondrial factors to exit, whereas anti-
apoptotic members such as Bcl-2, Bcl-XL and Bcl-w stabilize the membrane. Thus, cytochrome c, 
Smac/Diablo or HtrA2/Omi are released to the cytosol, which triggers the commitment step of the 
mitochondrial apoptotic cascade (Kluck et al., 1997; Yang et al., 2003). The intrinsic and extrinsic 
apoptotic pathways converge on the executioner cysteine-aspartic acid proteases (caspases)-3 and 7, 
which lyse a number of cellular protein targets, including the DNA-repair protein poly (ADP-
ribose) polymerase; inactivation of the latter promotes apoptosis (Fulda and Debatin, 2006). 
However, release of Smac/Diablo or HtrA2/Omi from the mitochondrion does not directly activate 
caspase; rather these factors block the action of the protein inhibitor of apoptosis that normally acts 
to suppress caspases. Finally, there is also a caspase-independent mitochondrial pathway in which 
apoptosis-inducing factor and endonuclease G are released to the cytosol (Susin et al., 1999). The 
translocation of these factors leads to DNA fragmentation which is the hallmark of apoptosis.  
Mitochondrial permability is controlled by the permeability transition pore complex which 
regulates the flow of small molecules across the mitochondrial membrane. Pore opening occurs in 
response to elevated Ca2+ concentrations, increased ROS and depleted adenine nucleotides 
(Kroemer et al., 1997). Permeability transition pore opening in turn dissipates the proton gradient, 
uncouples oxidative phosphorylation and decreases ATP formation. In consequence, antioxidant 
molecules such as glutathione exit the mitochondrion which further decreases the capacity to 
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detoxify locally generated ROS (Mari et al., 2009). The release of cytochrome c from the 
mitochondrion sets in train the activation of apoptotic death.  
The permeability transition pore is a complex arrangement of proteins including the adenine 
nucleotide translocator, which exchanges ATP and ADP (Marzo et al., 1998a; Brenner et al., 2000), 
the voltage-dependent anion channel (also termed porin), the soluble mitochondrial matrix protein 
cyclophilin D (Woodfield et al., 1998), a number of Bcl-2 family proteins (Marzo et al., 1998b; 
Shimizu et al., 1999), the peripheral benzodiazepine receptor and several proteins that regulate 
energy metabolism (e.g., hexokinase II and creatine kinase) (Marzo et al., 1998a). Several genes 
encoding components of the mitochondrial permeability transition pore including the peripheral 
benzodiazepine receptor, the associated protein Prax-1, and the energy-metabolising enzyme 
creatine kinase, are overexpressed in some tumours (Kanazawa et al., 1998; Venturini et al., 1998; 
Galiegue et al., 1999).  
While the pro-apoptotic Bax may be down-regulated in cancer cells (Brimmell et al., 1998), 
Bcl-2 or its anti-apoptotic homologues are frequently overexpressed (Kroemer et al., 1997). This 
shifts the balance in the cancer cell toward the prevention of apoptosis. Thus, an important 
adaptation is that the phosphatidylinositide 3-kinase (PI3K)/Akt signaling cascade inhibits pro-
apoptotic Bcl-2 factors and positively regulates the anti-apoptotic factor Bcl-2 (Skorski et al., 1997; 
Pugazhenthi et al., 2000). As described above, this shift in Bcl-2 factor composition stabilizes the 
outer mitochondrial membrane. PI3K/Akt has additional survival actions in tumour cells in that it is 
able to impair signaling by the pro-apoptotic JNK MAP kinase, enhance glucose uptake by 
transporters and activate glycolytic enzymes, such as hexokinase (Kroemer et al., 1997; Skorski et 
al., 1997; Pugazhenthi et al., 2000) These adaptations shift the capacity for energy production 
toward the glycolytic pathway that characterises the cancer cell. 
 
Biosynthetic roles of the mitochondrion in normal and cancer cells  
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Some important steps in lipid metabolism occur in the mitochondrion. While fatty acid 
synthesis occurs primarily in the cytoplasm, β-oxidation to produce ATP occurs in mitochondria. 
However, the mitochondrion also has a central role in the biosynthesis of phospholipids and 
triglycerides. The first step in the phospholipid synthesis pathway is the esterification of α-glycerol 
phosphate by acyl-CoA to produce lysophosphatidic and phosphatidic acids (Zborowski and 
Wojtczak, 1969; Bremer et al., 1976). Some phospholipids, such as phosphatidylcholine, 
phosphatidylserine and phosphatidylinositol, are synthesized in other organelles and transported to 
the mitochondrion where further biotransformation occurs. Cardiolipin, a characteristic 
phospholipid of the inner mitochondrial membrane, is synthesized within this organelle (Hostetler 
and van den Bosch, 1972).  
In mammals, fatty acids are activated to acyl-CoAs on the outer mitochondrial membrane 
before entering the glycerolipid biosynthetic pathway via glycerol-3-phosphate acyltransferase. 
Highly proliferative cancer cells have an increased requirement for lipids for the assembly of cell 
membranes (Samudio et al., 2009; Zaugg et al., 2011). Increased expression of fatty acid synthase 
in tumour cells promotes formation of long-chain fatty acids and confers a growth advantage 
(Sabine et al., 1967; Ookhtens et al., 1984). Indeed, fatty acid synthase inhibition decreases the rate 
of cancer cell proliferation and promotes apoptosis, as reflected by increased caspase-3 activation, 
down-regulation of anti-apoptotic proteins and the release of cytochrome c (Pizer et al., 1998; De 
Schrijver et al., 2003).  
 
Lipid synthesis and biotransformation in cells 
Fatty acids perform structural roles in cells by modulating membrane fluidity and the 
arrangement of receptors and other proteins in plasma membrane lipid rafts (Spector and Yorek 
1985). Naturally occurring long-chain fatty acids of 18-22 carbons in length are stored in cell 
membranes as triglycerides or phospholipids. Triglycerides are composed of three fatty acid 
residues connected to the hydroxyl groups of glycerol via ester linkages (Figure 1a). 
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Phosphoglycerides are the major phospholipid class, and are comprised of five components: two 
fatty acids, glycerol, a phosphate and an alcohol (Figure 1b). Subclasses are designated according to 
the alcohol group; thus phosphatidylcholines contain the choline group (Figure 1c). Other common 
alcohols include serine, ethanolamine, and inositol. Phosphatidates share this same basic structure 
but lack the alcohol group, and are intermediates in the biosynthesis of many phosphoglycerides. 
The glycerol group may also be substituted with sphingosine (2-amino-4-octadecene-1,3-diol), 
giving rise to sphingomyelins.  
Constituent fatty acids in membranes are either saturated (contain no carbon-carbon double 
bonds, as exemplified by palmitic acid (C16:0)), mono-unsaturated (contain only one olefinic bond; 
such as oleic acid (18:1 n−9) or polyunsaturated (PUFAs, that possess multiple olefinic bonds, 
typified by ω-6 arachidonic acid (20:4 n-6) and ω-3 eicosapentaenoic acid (20:5 n-3); Figure 1d). 
The double bonds in naturally occurring unsaturated fatty acids are primarily in the cis 
configuration, which kinks the carbon chain and imparts greater membrane fluidity. 
The carbon atoms of fatty acid chains are numbered starting from the carboxyl group and 
the carbon at the distal end of the molecule is the ω-carbon. Monounsaturated fatty acids and PUFA 
are classified by the position of the olefinic bond that is furthest from the carboxylate, and this is 
indicated in the lipid number notation. Thus, arachidonic acid (20:4 n-6) is a C20 fatty acid that has 
four olefinic bonds, with the double bond furthest from the carboxylate located six bonds from the 
ω-carbon (to produce a ω-6 olefinic bond). 
Release of fatty acids from their esterified phospholipid forms in cell membranes is 
mediated by phospholipase A2. Free PUFAs are substrates for cyclooxygenase (COX), 
lipoxygenase (LO) and cytochrome P450 (CYP) enzymes that generate multiple metabolites that 
have diverse homeostatic functions (Figure 2; Spector and Yorek 1985; Oates et al., 1988; Oliw, 
1994; Chen et al., 1995; Murray, 1999; Marden et al., 2003). Together, these enzymes produce 
prostaglandins, thromboxanes, fatty acid peroxides and their downstream leukotrienes, hydroxyfatty 
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acids and epoxides. In comparison, saturated fatty acids primarily undergo CYP-dependent 
oxidation to the corresponding ω- and ω-1 hydroxy acids.  
Apart from free fatty acids there is evidence that certain lipids may be present at increased 
levels in cancer cells. Thus, phosphocholine derivatives are increased in cancer cells and solid 
tumours (Ackerstaff et al., 2003) and plasma triglycerides are reportedly higher in women with 
invasive breast cancers (Goodwin et al., 1997). Some important enzymes involved in fatty acid 
biotransformation are also differentially expressed in cancers. Over-expression of COX and CYP 
enzymes promotes the formation of certain prostaglandin and epoxide metabolites that influence the 
fate of cells, including the rate of proliferation and the inhibition of apoptosis (Tsujii et al., 1997; 
Jiang et al., 2005). Moreover PUFA-derived metabolites modulate signaling pathways such as the 
extracellular signal-regulated kinase (ERK) and PI3K/Akt that have been implicated in 
tumourigenesis. As discussed below, inhibition of the formation of these PUFA metabolites 
modulates apoptosis and other aspects of tumour growth (Chen et al., 2009). Moreover, inhibition 
of the enzymes that mediate PUFA biotransformation has proven successful in the prevention of 
experimental tumour progression in vitro and in vivo (Koehne and DuBois, 2004; Chen et al., 
2009). However, at present there is a deficiency of inhibitory agents that are well tolerated over the 
prolonged treatment periods required during anticancer chemotherapy. 
 
The potential of lipids as anticancer agents that act at the mitochondrion 
Fatty acids are thought to uncouple oxidative phosphorylation and decrease ATP production 
by facilitating the leakage of protons across the lipid mitochondrial membrane. Uncoupling is 
greatest with C12–C16 saturated and longer cis-unsaturated fatty acids (Korshunov et al., 1998; 
Bernardi et al., 2002). For example, 5 µM laurate (C12-saturated) effectively inhibited H2O2 
production by mitochondria (Korshunov et al., 1998). Free fatty acids also impair electron transport 
and activate apoptosis by releasing cytochrome c from the inner mitochondrial membrane. There is 
increasing evidence that several classes of naturally occurring and synthetic lipids have the potential 
 10 
for development as anticancer agents that mediate their effects, at least in part, at the 
mitochondrion. However, some of these lipid-mediated anti-mitochondrial actions may be indirect, 
by modulating intracellular signaling pathways.  
(a) Naturally occurring free fatty acids and synthetic analogues 
(i) Saturated fatty acids 
In the non-ionised state medium and long-chain fatty acids readily penetrate the 
mitochondrial membrane (McLaughlin and Dilger, 1980; Gutknecht, 1988; Kamp and Hamilton, 
1992). Butyric acid and similar short-chain fatty acids induce cell cycle arrest and apoptosis by 
dissipating the mitochondrial membrane potential (ΔΨ), leading to growth arrest and apoptosis in 
colon carcinoma cells in vitro, as evidenced by activation of caspase-3 (Heerdt et al., 1997). In a 
small structure-activity study, the C4-butyric acid inhibited the growth of the human colonic 
adenocarcinoma cell lines HT-29, Colo-320, and SW-948 (IC50s 0.55-2.28 mM), while C3-
propionic acid was less potent and C5-valeric and C2-acetic acids were ineffective (Figure 3, Table 
1; Milovic et al., 2000). The apoptotic mechanism of butyric acid in colon cancer cells is mediated 
at least in part by inducing overexpression of the pro-apoptotic protein bak, which alters the 
bak/bcl-2 ratio (Hague et al., 1997; Ruemmele et al., 1999), but not by modulating ROS or ATP 
production (Heerdt et al., 1997). Bromo-analogues of butyric and propionic acids (IC50s 0.13-0.39 
mM) were several-fold more potent pro-apoptotic agents than butyrate, but also produced some 
cytotoxicity, so cautious development of these molecules as potential mitochondrially-targeted 
agents is warranted (Milovic et al., 2000).  
Longer-chain saturated fatty acids also act at the mitochondrion to activate apoptosis. 
Palmitic acid (C16:0) decreased ΔΨ and effected cytochrome c release, which induced the 
proteolysis of poly-ADP ribose polymerase and the fragmentation of DNA (de Pablo et al., 1999). 
This may also be a process of endogenous importance because long chain fatty acids can be 
generated intracellularly by activation of phospholipase A2. In addition, such free fatty acids may 
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also accumulate in mitochondria following exposure of cells to stimuli such as oxidative stress or 
increased Ca2+ concentrations (Broekemeier and Pfeiffer, 1995) 
13-Methyltetradecanoic acid is an iso-C15 branched-chain saturated fatty acid that has been 
found to disrupt mitochondrial integrity and induce apoptosis in a wide range of cancer cell lines 
(Figure 3, Table 1; Yang et al., 2000; Wongtangtintharn et al., 2005; Lin et al., 2012). Induction of 
apoptosis by 13-methyltetradecanoic acid was rapid and was detected after only 2 hours of 
treatment over the concentration range 0.04-0.35 mM (Lin et al., 2012). In some cell types 
apoptosis appeared to be caspase-independent pathway but, in human bladder cancer cells, 13-
methyltetradecanoic acid down-regulated Bcl-2, up-regulated Bax, promoted mitochondrial 
dysfunction and cytochrome c release, and activated caspases (Lin et al., 2012). 13-
Methyltetradecanoic acid also inhibited the PI3K/Akt survival cascade and activated the pro-
apoptotic p38 and JNK MAP kinase pathways (Lin et al., 2012). 
In vivo growth of the prostate carcinoma cell line DU 145 and hepatocarcinoma-derived 
LCI-D35 cells after orthotopic implantation of tumour xenografts into nude mice was also inhibited 
by 13-methyltetradecanoic acid (35-105 mg/kg/day). Apoptosis was induced without evidence of 
major toxicity, which suggests that 13-methyltetradecanoic acid could be a potential candidate for 
chemotherapy of human cancers (Yang et al., 2000). 
(ii) Unsaturated fatty acids 
Naturally occurring PUFAs also modulate cell proliferation and apoptosis. The ω-3 PUFA 
eicosapentaenoic acid (20:5 n-3) is incorporated into mitochondrial phospholipids, which has a 
number of consequences for mitochondrial function, including decreased mitochondrial membrane 
potential and ATP production, increased ROS generation and increased apoptosis (Colquhoun, 
2009). ω-6 PUFA also have the potential to activate apoptosis in human cancer cell lines by 
promoting lipid peroxidation (Cao et al., 2000). 
Conjugated linoleic acid (CLA) is a mixture of geometric isomers of linoleic acid (Figure 3) 
that decreases the viability of various cancer cell types, including those of the skin, forestomach, 
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mammary gland and colon. CLA (32 µM), but not linoleic acid, inhibited growth of rat mammary 
epithelial cell organoids that was mediated both by a decrease in DNA synthesis and increased 
apoptosis (Ip et al., 1999). In vivo activity was also noted and feeding CLA to rats that harboured 
premalignant lesions induced apoptosis in a mammary tumour cell line, as determined by a decrease 
in expression of the anti-apoptotic bcl-2 (Table 1; Ip et al., 2000). Cho et al. (2003) showed that 
CLA inhibited the proliferation of HT-29 human colorectal cancer cell line by activating apoptosis, 
due in part to inhibition of PI3K/Akt signalling. Similarly, the 10-trans,12-cis CLA isomer (5 µM) 
inhibited the proliferation of Caco-2 colon carcinoma cells, and enhanced apoptosis in premalignant 
lesions, but not in normal cells (Kim et al., 2002).  
Other types of naturally-occurring conjugated fatty acids that have pro-apoptotic actions 
include conjugated linolenic acids such as α-eleostearic acid (9-cis,11-trans,13-trans-18:3) from 
bitter gourd oil and calendic acid (8-trans,10-trans-12-cis-18:3) from pot marigold. α-Eleostearic 
acid was quite potent relative to CLA isomers against tumour cells in vitro (Tsuzuki et al., 2004). α-
Eleostearic acid (40 µM) promoted lipid peroxidation and apoptosis in MDA-MB-231-derived cell 
lines as evidenced by a loss of mitochondrial membrane potential and the release of apoptotic 
factors from the mitochondrion. When treated with α-eleostearic acid in the presence of α-
tocotrienol (20 µM), growth inhibition and apoptosis did not occur, thus providing further support 
for involvement of ROS-mediated lipid peroxidation in the apoptotic mechanism (Grossmann et al., 
2009). 
The monounsaturated fatty acid vaccenic acid (11-trans-18:1 n-7) decreased cell growth, 
induced DNA fragmentation and depleted cytosolic glutathione levels; these findings are consistent 
with activation of the intrinsic pathway of apoptosis by lipid peroxides (Miller et al., 2003). Punicic 
acid (18:3 n-5) is an ω-5 long chain PUFA found in pomegranate seed oil. In MDA-MB-231 and 
MDA-ERα7 cells punicic acid disrupted the mitochondrial membrane potential and induced 
apoptosis, apparently also by a prooxidant mechanism (Grossmann et al., 2010). DNA 
 13 
fragmentation was observed after 24 h treatment of cells at concentrations in the range 10-100 µM 
(Gasmi and Sanderson, 2010).  
Jacaric acid is a linolenic acid isomer obtained from jacaranda that has a conjugated triene 
system and elicits potent antitumour effects both in vitro and in vivo in nude mice into which DLD-
1 cells had been xeno-transplanted (Shinohara et al., 2012). When compared with natural 
conjugated linolenic acids in DLD-1 adenocarcinoma cells the antitumour effects of jacaric acid 
were most potent and correlated with increased ROS production. Thus, jacaric acid induced 
concentration- and time-dependent LNCaP cell death in part through activation of intrinsic 
apoptotic pathways, resulting in cleavage of caspase-3, -8 and -9, modulation of pro- and anti-
apoptotic Bcl-2 family of proteins and increased cleavage of poly (ADP-ribose) polymerase-1 
(Gasmi and Sanderson, 2013). 
Several dietary C18 unsaturated fatty acids have been tested for cytotoxicity and induction 
of apoptosis in human prostate cancer cells. These included three octadecatrienoic geometric 
isomers (α- and β-calendic and catalpic acids) and two mono-unsaturated C18 fatty acids (trans- 
and cis-vaccenic acid) in addition to jacaric and punicic acids (Figure 3, Table 1). Jacaric acid and 
four of its octadecatrienoic acid geometric isomers selectively induced apoptosis in both hormone-
dependent (LNCaP) and hormone-independent (PC-3) human prostate cancer cells when tested at 
concentrations around 10 µM, without affecting the viability of normal human prostate epithelial 
cells (Gasmi and Sanderson, 2013). Together these findings suggest that some of the pro-apoptotic 
actions of antitumour fatty acids may be cell type-specific. 
From the foregoing it is evident that most studies to date have focused on ROS generation 
by unsaturated fatty acids as the mechanism of their pro-apoptotic action. However, there may be 
additional, more selective, mechanisms that could be developed in synthetic anticancer fatty acids. 
In a recent study, a series of n-3 monounsaturated fatty acids of chain length C16-C22 was 
synthesized and evaluated in MDA-MB-468 breast cancer cells that stably overexpressed COX-2 
(Cui et al., 2012). This reflects the situation that may operate in many human cancers in which 
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COX-2 is upregulated. The longer chain C19-C22 analogues were found to inhibit proliferation and 
activate apoptosis; C16-C18 analogues were less active. PGE2 formation was decreased by the C19-
C22 analogues, consistent with COX-2 inhibition, which was supported by molecular modeling that 
revealed effective interactions with specific amino acid residues in the COX-2 active site. Strategies 
of this type, in which potential fatty acid drugs target a biotransformation enzyme present in 
tumours, may be worthy of further consideration. Such agents may enable approaches based on 
COX-2 inhibition to be retained, perhaps without the toxicity associated with conventional non-
steroidal anti-inflammatory drugs. 
(iii) Fatty acid analogues 
Tetradecylthioacetic acid (TTA) is a saturated fatty acid that has a sulphur atom inserted at 
the C3 position in the carbon chain. TTA (0.2-0.5 mM) decreased proliferation and induced 
apoptosis in a diverse range of tumour cell lines in vitro and in vivo (Tronstad et al., 2003; Iversen 
et al., 2006). Long-chain 3-thia-fatty acids in general also uncouple oxidative phosphorylation and 
dissipate the mitochondrial membrane potential (ΔΨ) by direct interaction with the adenine 
nucleotide translocator to open the mitochondrial permeability transition pore, which leads to 
decreased ATP production (Wieckowski and Wojtczak, 1998). In accord with this mechanism, TTA 
stimulates mitochondrial ROS production (Tronstad et al., 2001), leading to glutathione depletion 
which renders mitochondria susceptible to further damage (Tronstad et al., 2003). Activation of 
apoptosis was indicated by the release of mitochondrial cytochrome c that enhanced caspase-3 
activation and poly (ADP ribose) polymerase cleavage.  
TTA is resistant to mitochondrial β-oxidation and, compared with naturally occurring 
saturated fatty acids, is degraded relatively slowly to dicarboxylic acids by microsomal oxidation at 
the ω-carbon and sulphur atoms and by peroxisomal β-oxidation (Hvattum et al., 1991). This 
property could be useful in development of TTA and analogues as drugs since these molecules are 
likely to have superior durations of action in vivo. Indeed, a diet containing TTA increased the 
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vascularisation of colon cancer xenografts in mice and improved the survival of mice with leukemia 
xenografts (Jensen et al., 2007).  
Jasmonates are plant hormones that structurally resemble fatty acid esters (Figure 3). These 
agents interact directly with mitochondria in cancer cells to detach hexokinase-II from its location 
on the voltage-dependent anion channel in the mitochondrial permeability transition pore (Goldin et 
al., 2008). Indeed, the susceptibility in cancer cells to these molecules is dependent on the 
association of hexokinase with the mitochondrion. Pro-apoptotic mitochondrial actions of low 
millimolar concentrations of jasmonates include membrane depolarization, mitochondrial swelling, 
cytochrome c release and cell death; interestingly the agents were inactive in normal cells (Table 1; 
Fingrut and Flescher, 2002; Rotem et al., 2005).  
Correlations have been reported between methyl jasmonate cytotoxicity in a range of cell 
types and the extent of ATP depletion (Goldin et al., 2007). Glucose protected against this loss of 
ATP, whereas the glycolysis inhibitor, 2-deoxyglucose, synergised with methyl jasmonate (Fingrut 
et al., 2005; Heyfets and Flescher, 2007). Similar effects have been elicited by other hexokinase-
detaching agents, such as hypericin and clotrimazole, that also deplete ATP and decrease cell 
viability (Miccoli et al., 1998; Machida et al., 2006). These findings are consistent with the 
functional importance of hexokinase in glycolysis, which is a major pathway of ATP production in 
cancer cells. 
Taken together, a number of studies have found that endogenous fatty acids, including 
saturated and certain unsaturated analogues, activate apoptosis via the mitochondrial intrinsic 
pathway and impair ATP production. Frequently this may be due to increased ROS production 
which alters mitochondrial membrane potential, but the example of jasmonate, involving 
hexokinase detachment, illustrates the potential for further development of mitochondrially-targeted 
fatty acids that selectively disrupt energy metabolism in cancer cells. 
(b) Fatty acid metabolites 
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Several PUFA-derived metabolites have been shown to modulate signaling pathways that 
are implicated in tumourigenesis. Thus, inhibition of the enzymic formation of these fatty acid 
metabolites has been found to decrease cancer cell viability. Important metabolites that have 
emerged in this regard include COX-mediated PGE2, CYP-dependent epoxyeicosatrienoic acids 
(EETs) and certain LOX-mediated hydroxyeicosatetraenoic acids that inhibit apoptosis and enhance 
proliferation (Avis et al., 2001; Koehne and DuBois, 2004; Chen et al., 2009). An understanding of 
the involvement of fatty acid metabolites in the pathogenesis of cancer could open new avenues for 
the production of new and safer therapeutic and chemopreventive agents.  
Certain fatty acid biotransformation enzymes have been detected at high level in human 
cancers. Thus, COX-2 and CYP2J2 are over-expressed in many invasive human cancers (Tsujii et 
al., 1997; Jiang et al., 2005). COX-2-derived PGE2, LOX metabolites and CYP2J2-derived EETs 
are implicated in aggressive tumour behavior (Figure 4, Table 1; Avis et al., 2001; Koehne and 
DuBois, 2004; Hoque et al., 2005; Jiang et al., 2005). Mechanistic information is available for some 
of these metabolites. Thus, PGE2 and EETs enhance tumour cell proliferation and survival by 
activating the proliferative epidermal growth factor receptor (EGFR)/ERK MAP kinase and anti-
apoptotic PI3K/Akt signaling pathways (Chen et al., 2009).  
Inhibition of 5-LOX by MK886 induces apoptosis in both hormone-responsive (LNCaP) 
and hormone-unresponsive (PC3) prostate cancer cells (Ghosh and Myers, 1998). An immediate 
and sustained rise in cytosolic calcium is followed by mitochondrial uncoupling and cytochrome c 
release (Maccarrone et al., 2001). Soon after treatment cells underwent the mitochondrial 
permeability transition, followed by other apoptotic events, including externalization of 
phosphatidylserine and degradation of DNA (Ghosh and Myers, 1998). Cell death was prevented by 
direct addition of 5-HETE and analogues such as 5-HETE-lactone and 5-oxoeicosatetraenoic acid 
(50-500 nM; Ghosh and Myers, 1998). In breast cancer cells inhibition of 5-LOX, but not COX, 
reduced growth, increased apoptosis, down-regulated bcl-2, up-regulated bax, and caused G1 cell 
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cycle arrest (Avis et al., 2001). Lipid peroxidation and the depletion of mitochondrial glutathione 
have been linked to the activation of apoptotic Bcl-2 proteins in these cells.  
While the inhibition of biotransformation enzymes that generate lipid metabolites may be 
beneficial in the prevention of cancer progression, there is also increasing evidence emerging that 
ω-3 PUFAs undergo biotransformation to metabolites that inhibit carcinogenesis. Inhibition of 
protein kinase C by the parent ω-3 PUFAs eicosapentaenoic and docosahexaenoic acids activates 
apoptosis by down-regulating Bcl-2 (Denys et al., 2005); COX-2-derived ω-3 PGE3 was recently 
implicated in anti-cancer actions of ω-3 PUFAs (Szymczak et al., 2008). Epoxides of ω-3 PUFAs 
have also been shown to exert growth suppressing and anticancer effects. The 17,18-epoxide of 
eicosapentaenoic acid (ω-3-epoxy-eicosapentaenoic acid), but not other regio-isomeric epoxides of 
eicosapentaenoic acid, was shown to inhibit cell proliferation. At physiologically relevant 
concentrations, ω-3-epoxy-eicosapentaenoic acid induced apoptosis and cell cycle arrest of brain 
microvascular endothelial bEND.3 cells through activation of growth suppressing p38 MAP kinase 
and subsequent down-regulation of cyclin D1 (Cui et al., 2011). More recently, Zhang et al. (2013) 
showed that epoxygenase-mediated metabolites of the C22 ω-3 fatty acid docosahexaenoic acid 
exerted anticancer effects by suppressing vascular endothelial growth factor-mediated angiogenesis. 
Inhibition of angiogenesis resulted in a decrease in primary tumour growth and metastasis in vitro. 
By co-administration with t-AUCB, a soluble epoxide hydrolase inhibitor, the 19,20-epoxide was 
active in vivo, reducing tumour growth in the Lewis lung carcinoma model (Zhang et al., 2013). 
These actions were opposite to those of ω-6 arachidonic acid-derived EETs. However, at present, 
whether PUFA epoxides also interact directly with the mitochondrion, in addition to their indirect 
actions mediated by signaling cascades, to elicit these actions is unclear. 
(c) N-acyllipids 
(i) ceramides 
Ceramides are a class of N-acylated sphingoid bases (Figure 4) found at high concentration 
in cell membranes and cytosolic organelle membranes and act as intracellular second messengers in 
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the regulation of growth, differentiation, and apotosis. Ceramide accumulation occurs after 
treatment of cells with apoptotic agents including chemotherapeutic agents, or after treatment with 
saturated fatty acids such as palmitic acid (Merrill and Jones, 1990). Direct addition of ~1 µM 
ceramide to mitochondria and ceramide accumulation in cells both produced changes in the 
mitochondrial transmembrane potential by forming channels or targeting Bcl-2 family members that 
leads to translocation of cytochrome c from mitochondria to the cytoplasm, and caspase-3 
activation (Garcia-Ruiz et al., 1997). Because respiratory complex III is inhibited by C2-ceramide 
the proximal effects of ceramide in cells are mediated at least in part at the mitochondrion (Gudz et 
al., 2007). Inhibition of p38 and JNK MAP kinases decreased ceramide-induced apoptosis by 
preventing the loss of mitochondrial transmembrane potential and inhibition of caspase activation 
(Chen et al., 2008). This suggests that ceramides may operate by both direct and indirect 
mechanisms to exert apoptotic actions at the mitochondrion. 
In tumour cells the cell-permeable shorter-chain exogenous C2- and C6-ceramide analogs, 
but not the longer-chain, naturally-occurring C16-ceramide, activated intrinsic apoptotic events at 
concentrations ≥ 10 µM, including caspase-3 activation, poly (ADP-ribose) polymerase 
degradation, and mitochondrial cytochrome c release (Fillet et al., 2003; Flowers et al., 2012). C6-
ceramide increased ROS levels in MDA-MB-231 cells, shifted the Bax:Bcl-2 ratio and depolarized 
the mitochondrial membrane (Flowers et al., 2012). Thus, analogues containing fatty acids of 
medium chain length may be particularly suited to development as putative anticancer agents that 
target the mitochondrion. 
(ii) N-Acylethanolamines  
Anandamide (Figure 4) and other N-acylethanolamines reportedly promote apoptosis and/or inhibit 
cell proliferation (Table 1; Schwarz et al., 1994; De Petrocellis et al., 1998; Maccarrone et al., 
2000; Sarker et al., 2000). These molecules appear to act in part by increasing the inner 
mitochondrial membrane permeability at concentrations up to 100 µM (Epps et al., 1982). 
Anandamide and N-oleoylethanolamine exerted protonophoric effects in mitochondria due to 
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dissipation of the transmembrane potential and opening of the permeability transition pore 
(Wasilewski et al., 2004). Long-chain N-acylethanolamines, including anandamide, accumulate in 
mammalian tissues under a variety of pathological conditions (Schmid et al., 2002). Indeed they 
have been detected at levels up to 500 nmol/g of infarcted canine myocardium. They have also been 
shown to inhibit the growth of various cancer cell lines in vitro. Cancer tissues usually contain 
substantially higher concentrations of these lipids than adjacent benign tissue, when normalized to 
wet weight, since most tumours also contained higher levels of phospholipids.  
Despite these apparent pro-apoptotic effects of N-acylethanolamines in cancer cells there is 
also evidence for protective effects in cells. The long-chain N-palmitoyl- and N-
stearoylethanolamine (100 µM) inhibited lipid peroxidation in hepatic mitochondria, which is 
consistent with membrane protective properties (Gulaya et al., 1998). The beneficial effect of N-
acylethanolamines on cell survival when oxygen availability is low depends in part on the inhibition 
of lipid oxidation. The effect of different N-acylethanolamines on lipid peroxidation seems to be 
dependent on the length of acyl chain as was found for other effects of N-acylethanolamines in the 
cell (Gulaya et al., 1993). These findings highlight the need for clarification of the relationships 
between chain length in N-acylethanolamines and their cellular actions prior to development of 
analogues as potential anticancer drugs. 
Very recently novel fatty acid derivatives of isopropylaminopropanol containing C16:0 or 
C18:1 substituents were prepared and were found to be effective against the growth of hepatoma 
cells in vitro (IC50s ~5-10 µM) and in vivo xenografts when dosed at 25 mg/kg (Cao et al., 2013). 
These agents inhibited the activity of multiple kinases, including the prosurvival Akt, which 
increased caspase and poly (ADP-ribose) polymerase cleavage. It will now be of interest to explore 
in greater detail how these agents modulate mitochondrial activity to elicit anticancer actions. 
(d) Phospholipid derivatives 
(i) Cardiolipin 
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Cardiolipin is a structurally complex diphosphatidylglycerol lipid that is synthesised by the 
mitochondrion (Figure 4). Mitochondrial respiratory complexes have been shown to require 
cardiolipin for full function. Palmitic acid decreased the levels of cardiolipin, which is responsible 
for insertion and retention of cytochrome c in the inner membrane of the mitochondrion (Schlame et 
al., 2000; Ostrander et al., 2001). Decreased cardiolipin and altered mitochondrial function mediate 
palmitate-induced breast cancer cell death by promoting ROS production and release of cytochrome 
c by permeabilization of the outer membrane (Petrosillo et al., 2003); overexpression of the anti-
apoptotic Bcl-2 family members Bcl-xL and Bcl-w blocked apoptosis (Kuwana et al., 2002).  
(ii) ether phospholipids 
The ether phospholipids are a promising class of antitumour lipids that act in part at the 
mitochondrion. Ether phospholipids have one or more glycerol carbons bonded to an alkyl chain via 
an ether linkage, as opposed to the usual ester linkage. Ether phospholipids include miltefosine, 
ilmofosine, perifosine, edelfosine and erucylphosphocholine (Figure 4). 
The novel alkylphospholipid analog perifosine is a PI3K/Akt inhibitor (Table 1; Kondapaka 
et al., 2003) that inhibits growth at low micromolar concentrations and activates the intrinsic 
pathway of apoptosis in cells as evidenced by increased caspase activity and cleavage of poly(ADP-
ribose) polymerase. Activated caspase-8 cleaves Bid which migrates to mitochondria and induces 
cytochrome c release (Chiarini et al., 2008). Interestingly, these agents are effective in rapidly 
proliferating cancer cells, but not quiescent normal cells.  
Clinical evaluation of perifosine has been conducted, or is continuing, in patients with 
cancers of the endometrium, breast, prostate, bladder and other tissues. In 2010 perifosine was 
evaluated in phase II trials for metastatic colon cancer and extended the time taken for tumour 
progression. However, in 2013, it was announced that the drug failed trials in patients with relapsed 
or relapsed/refractory multiple myeloma (http://www.aezsinc.com/en/page.php?p=60&q=550, 
accessed June 28, 2013). When used in combination with the multikinase inhibitor sorafenib, 
perifosine induced intrinsic apoptosis in cells and antitumour effects in NOD/SCID mice with 
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Hodgkin lymphoma cell line xenografts (Locatelli et al., 2013). In cell lines the combination 
treatment inhibited MAP kinase, activated PI3K/Akt phosphorylation and suppressed growth; 
synergistic induction of mitochondrial dysfunction and cell death was noted. In in vivo xenograft 
studies there was a reduction in tumour burden, increased survival time, increased apoptosis and 
necrosis in perifosine/sorafenib-treated animals compared with single agents. Subsequently, 
treatment of human leukemia T cells with the PI3K/Akt inhibitor perifosine and etoposide also 
effected synergistic induction of apoptosis by dual activation of intrinsic and extrinsic pathways 
(Nyåkern et al., 2006). This combination produced a two-fold increase in caspase-8 activation, and 
a marked increase in caspase-9, caspase-3, and poly(ADP-ribose) polymerase cleavage, as well as 
increased Bim, Bid and Bcl-XL expression. Etoposide and perifosine induced leukemic cell death in 
part by inactivation of the PI3K/Akt pathway that increased mitochondrial dysfunction. However, it 
is of considerable interest that ether phospholipids proved to be highly effective when used in 
combination with other anticancer agents. 
Edelfosine induces changes in mitochondrial membrane permeability and inhibits 
mitochondrial respiration (Burgeiro et al., 2013). Edelfosine, miltefosine, erucylphosphocholine 
and perifosine all activate the JNK MAP kinase pathway which induces apoptosis (Ruiter et al., 
1999; Nieto-Miguel et al., 2006). The mechanism involves direct activation of apoptosis by 
phosphorylation of the anti-apoptotic Bcl-XL (Kharbanda et al., 2000; Aoki et al., 2002). 
Edelfosine also disrupts the mitochondrial transmembrane potential, apparently by altering 
mitochondrial membrane phosphocholine content (Vrablic et al., 2001), promotes the cleavage of 
caspase-3 and poly (ADP-ribose) polymerase, and enhances production of ROS in human 
leukaemic T cells (Table 1; Cabaner et al., 1999; Gajate et al., 2000). Edelfosine-induced apoptosis 
is blocked by Bcl-2 (Mollinedo et al., 1997; Ruiter et al., 2003; Hideshima et al., 2006).  
New fluorescent edelfosine analogs retained the pro-apoptotic activity of the parent, and 
colocalized with mitochondria (Mollinedo et al., 2011). These agents induced the swelling of 
isolated mitochondria, consistent with an increase in mitochondrial membrane permeability. Free 
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radical scavengers did not affect swelling, suggesting that ROS do not contribute. It was suggested 
that edelfosine promoted a redistribution of lipid rafts from plasma membrane to mitochondria 
(Mollinedo et al., 2011). In summary, ether phospholipids have potential for development as a 
novel class of anticancer agents that act in part by altering mitochondrial function. 
 
Challenges in the development of lipid molecules as drugs 
Fatty acids differ from typical drugs in that there is a large degree of molecular flexibility 
inherent in fatty acid alkyl chains. Although fewer than 10 rotatable bonds is seen as desirable for 
adequate oral bioavailability and membrane permeation (Veber et al., 2002), fatty acids possess 
satisfactory pharmacokinetic profiles. For example, medium and long chain dietary fatty acids are 
readily absorbed and distributed throughout all tissues of the body including the brain. Moreover 
the ether phospholipid edelfosine is orally active despite possessing 27 rotatable bonds. The 
favorable pharmacokinetic profiles of fatty acids may be in part due to the facilitation of uptake and 
transport (Ramirez et al., 2001), including binding to serum albumin and incorporation into 
triglycerides, that distribute these essential nutrients throughout the body. However, the flexibility 
of fatty acids does present challenges in drug design, particularly in ligand-based approaches where 
the structure of the drug target is unknown. Conformational analysis is a critical step in 
pharmacophore and pseudo-receptor modeling, and the high number of rotatable bonds can make 
identification of low-energy and bioactive conformations difficult and time-consuming. When the 
structure of the drug target is known ligand docking approaches are straight forward, as exemplified 
by our recent modeling of the interactions of a series of novel ω-3 monounsaturated fatty acids in 
the COX-2 active site (Cui et al., 2012). 
As mentioned earlier, fatty acids are subject to numerous metabolic processes mediated by 
COX, LOX and CYP enzymes that can present challenges for the development of lipid-derived 
drugs that have acceptable in vivo stability. Furthermore, lipid-derived mediators (e.g. 
prostaglandins, epoxides, resolvins and others) frequently possess labile functional groups that are 
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also readily metabolized. Improvement of the metabolic as well as chemical stability of lipid-based 
drugs, particularly those derived from prostaglandins (Collins and Djuric 1993; Das et al., 2007) 
and lipoxin (Duffy and Guiry 2010), has received much attention and a number of strategies have 
been developed and successfully employed in drug discovery settings. These strategies commonly 
involve addition of functional groups to block particular metabolic processes, or bioisosteric 
replacement of labile functional groups with more robust equivalents. For example, incorporation of 
a heteroatom in alkyl chains at the position β to the carboxylate functionality can improve the 
duration of action in vivo, as shown by the prostaglandin analogue cicaprost (Hildebrandt et al., 
1989). These approaches have led to the development of numerous marketed drugs, which clearly 
demonstrate the potential of lipids as drugs and as lead compounds in drug discovery. 
 
Development of new mitochondrial targeted inhibitors in cancer chemotherapy 
Evidence is increasing that fatty acids and other lipids act in part by modulation of 
mitochondrial function. These actions may be direct, such as the detachment of hexokinase from the 
cancer cell mitochondrial transition pore complex or by uncoupling of respiratory complexes that 
produce ATP. Alternately, some lipid agents may act indirectly by increasing ROS activity in cells 
or by interfering with cell signaling pathways, to perturb the balance of pro- and anti-apoptotic bcl-
2 proteins that regulate mitochondrial membrane stability. It should be noted, however, that 
mitochondrial actions of certain lipid-based molecules may operate alongside non-mitochondrial 
mechanisms, including altered membrane raft composition or altered gene regulation.  
A point of major interest that has emerged from cellular studies is that fatty acid derivatives 
often exhibit activity against cancer cells, but not normal cells. This appears to be a property that 
augers well for new anti-cancer drug development based on lipids. The available information does 
not provide a full understanding for this selectivity because the targeted pathways may be present in 
both cell types. It will now be of major importance to define in detail the defects present in 
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mitochondria of cancer cells so that new drugs may be developed that have optimal potency with 
fewer off-target actions. 
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Table 1: Naturally occurring and synthetic fatty acids and other lipids: mitochondrial actions of potential value in cancer chemotherapy 
 
   
Fatty acid derivative Mitochondrial actions Pathways effected Function References 
Butyric acid Dissipation of the mitochondrial 
membrane potential (ΔΨ)  
Caspase-3 activation ↑Apoptosis 
Growth arrest 
Heerdt et al. 1998 
Milovic  et al. 2000 
Bromo- analogues of 
butyric and propionic 
acids 
↑ROS, DNA damage   ↑Apoptosis Milovic  et al. 2000 
Palmitic acid ↓Mitochondrial membrane ΔΨ, 
cytochrome c release 
 ↑Apoptosis 
↑Cell death 
Merrill and Jones, 1990 
Schlame et al., 2000 
Ostrander  et al., 2001 
13-Methyltetradecanoic 
acid 
Disrupted mitochondrial integrity 
and caused dysfunction, 
cytochrome c release 
↑Bax, ↓Bcl-2 
Caspase-3 activation 
↓pAkt 
↑p38 and JNK MAP kinase 
↑Apoptosis 
Growth inhibition 
Yang et al., 2000 
Wongtangtintharn et 
al., 2005,  
Lin et al., 2012 
Arachidonic acid (AA)-
derived PGE2 
 ↑EGFR/ERK MAP kinase 
↑PI3K/Akt 
↑Survival 
↑Proliferation 
Chen et al. 2009 
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Eicosapentaenoic acid 
(EPA)  
↑ATP glycolysis, ↑ROS, 
↓mitochondrial membrane ΔΨ 
Caspase-3 activation 
Protein kinase C inhibition, ↓Bcl-
2 
↑Apoptosis 
Growth inhibition 
Denys et al., 2005 
Colquhoun, 2009 
 
EPA-derived epoxides  p38 MAP kinase ↑Apoptosis 
Growth inhibition 
Cui et al., 2011 
 
Docosahexaenoic acid 
(DHA) 
 Protein kinase C inhibition, ↓Bcl-
2 
↑Apoptosis Denys et al., 2005 
Conjugated linoleic acid 
(CLA) 
↓DNA synthesis ↓Bcl-2, ↓PI3K/Akt ↑Apoptosis 
↓Proliferation 
Ip et al., 1999 
Ip et al., 2000 
Kim et al., 2002 
Jacaric acid ↑ROS  ↓Bcl-2, caspase-3, -8 and -9 
activation, Poly (ADP-ribose) 
polymerase cleavage 
↑Apoptosis 
(intrinsic and/or 
extrinsic pathways) 
Shinohara et al., 2012 
Gasmi and Sanderson, 
2013  
α-Eleostearic acid ↓Mitochondrial membrane ΔΨ, 
↑DNA fragmentation,  
↑lipid peroxidation 
 ↑Apoptosis Tsuzuki et al., 2004, 
Grossmann et al., 2009 
Vaccenic acid ↑DNA fragmentation  Growth inhibition Miller et al., 2003 
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↓Cytosolic 
glutathione 
↑Cell death 
Punicic acid Disrupted the mitochondrial 
membrane ΔΨ, ↑DNA 
fragmentation, ↑lipid 
peroxidation 
Caspase-3 and -9 activation 
↓Bcl-2 (decreased Bcl-2:Bax 
ratio) 
↓pAkt 
↑Apoptosis Grossmann et al., 
2010, Gasmi and 
Sanderson, 2010 
Tetradecylthioacetic 
acid 
↑Mitochondrial proliferation, 
↑oxidative stress, ↑ROS 
Caspase-3 activation 
Poly (ADP-ribose) polymerase 
cleavage 
↑Apoptosis 
↓Proliferation  
Tronstad et al., 2001 
Lin et al., 2002  
Tronstad et al., 2003 
 
Jasmonates Cytochrome c release, membrane 
depolarization, swelling of 
mitochondria, ↓ATP 
 ↑Cell death Fingrut and Flescher, 
2002  
Rotem et al., 2005  
Fingrut et al., 2005 
Heyfets and Flescher, 
2007 
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Goldin et al., 2007  
Epoxyeicosatrienoic 
acids (EETs) 
 ↑EGFR/ERK 
↑PI3K/Akt 
↑Survival  
↑Proliferation 
Chen et al. 2009 
HETEs and downstream 
leukotrienes 
Inhibition of 5-LOX depleted 
mitochondrial glutathione and 
↑lipid peroxidation 
↑apoptotic Bcl-2 family proteins ↑Survival  
Enhanced growth 
Ghosh and Myers, 
1998 
Avis et al. 2001 
Hoque et al. 2005  
Short chain ceramides Cytochrome c release, 
↓mitochondrial membrane ΔΨ, 
↑ROS 
Caspase-3 activation, ↓Bcl-2: Bax 
ratio, ↑p38 and JNK MAP kinase 
phosphorylation, Poly (ADP-
ribose) polymerase cleavage 
↑Apoptosis Fillet et al., 2003 
Flowers et al., 2012 
Anandamide and N-
acylethanolamines  
↑Permeability of inner 
mitochondrial membrane, ↑↓lipid 
peroxidation*, energetic and 
permeability transition 
alterations, Ca2+ overload and 
PTP modulation 
 ↑↓Apoptosis 
↑↓proliferation 
Epps et al., 1982 
Gulaya et al., 1993 
Schwarz et al., 1994 
De Petrocellis et al., 
1998 
Maccarrone et al., 2000 
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Sarker et al., 2000 
Wasilewski et al., 2004 
Cardiolipin Involved in ROS-promoted 
cytochrome c release 
Membrane targeting of Bid, 
activation of Bax 
↑Apoptosis Kuwana et al., 2002 
Perifosine ↑Cytochrome c release, 
mitochondrial oxidative 
phosphorylation disruption, 
induction of permeability 
transition 
Akt inhibition 
Caspase-3, -8 and -9 activation 
↑JNK MAP kinase translocation 
↑Apoptosis Kondapaka et al., 2003 
Nieto-Miguel et al., 
2006 
Chiarini et al., 2008 
Burgeiro et al., 2013 
Edelfosine Mitochondrial dysfunction via 
multiple mechanisms 
Altered mitochondrial membrane 
ΔΨ, ↑DNA fragmentation, ↑ROS  
Caspase-3 activation 
Poly (ADP-ribose) polymerase 
cleavage 
↑Apoptosis Cabaner et al., 1999 
Gajate et al., 2000 
Mollinedo et al., 2011 
Isopropylaminopropanol 
derivatives (C16:0 and 
C18:1) 
 Inhibition of multiple pro-
survival kinases 
Growth inhibition Cao et al., 2013 
 
*dependent on fatty acid chain length and saturation 
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Figure legends 
Figure 1.  Chemical structures of fatty acids, triglycerides and phospholipids. (a) general structure 
of triglycerides; (b) general structure of phospholipids; (c)phosphatidylcholine; (d) 
important dietary fatty acids with carbon numbering.  
 
 
Figure 2.  PUFA biotransformation pathways. PUFA are released from their esterified form in cell 
membranes to free fatty acids. The enzymatic actions of cyclooxygenase (COX), 
lipoxygenase (LOX) and cytochrome P450 (CYP) signaling molecules with diverse 
homeostatic actions. 
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Figure 3.  Naturally occurring fatty acids with anticancer activity. 
 
 
Figure 4.  Chemical structures of important fatty acid metabolites and phospholipids, and general 
structures of ceramides and sphingomyelins. 
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